Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma

被引：0
作者：
Hiroyuki Takamatsu
Takeshi Yamashita
Takeharu Kotani
Aiko Sawazaki
Hirokazu Okumura
Shinji Nakao
机构：
[1] NTT WEST Kanazawa Hospital,Department of Internal Medicine
[2] Kanazawa University Graduate School of Medical Science,Cellular Transplantation Biology
来源：
International Journal of Hematology | 2010年 / 91卷
关键词：
Multiple myeloma; Ischemic heart disease; Bortezomib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A 79-year-old female patient with multiple myeloma who had no prior cardiac disease history developed an acute myocardial infarction on day 5 after receiving bortezomib and dexamethasone (BD). After treatment of coronary stenoses by stents, she received another course of BD therapy and developed angina pectoris on day 5 after the therapy. Bortezomib’s antitumor effect is due to the inhibition of proteasome activity. This inhibition may increase endothelial progenitor cell apoptosis and decrease endothelial nitric oxide synthase/nitric oxide (eNOS/NO), thus leading to coronary spasm. It is, therefore, important to carefully monitor patients being treated with bortezomib for the potential occurrence of ischemic heart disease.
引用
收藏
页码：903 / 906
页数：3
相关论文
共 176 条
[1]  
Richardson PG(2007)Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Blood 110 3557-3560
[2]  
Sonneveld P(2003)Clinical update: proteasome inhibitors in hematologic malignancies Cancer Treat Rev 29 33-39
[3]  
Schuster M(2006)Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma Clin Lymphoma Myeloma 7 131-134
[4]  
Irwin D(2006)Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report BMC Cancer 6 129-222
[5]  
Stadtmauer E(2008)Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib Int J Hematol 88 219-397
[6]  
Facon T(2007)Unexpected cardiotoxicity in haematological bortezomib treated patients Br J Haematol 138 396-388
[7]  
Harousseau JL(2010)Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance J Cardiovasc Med (Hagerstown) 11 386-814
[8]  
Ben-Yehuda D(2000)Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in Japan Br J Haematol 109 805-40
[9]  
Lonial S(2007)Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients Eur J Haematol 78 35-37
[10]  
Goldschmidt H(2010)Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Lancet Oncol 11 29-801
12345678910